Assoc Prof Toh Han Chong
National Cancer Centre Singapore
Division of Medical Oncology
Senior Consultant/Deputy Director, NCCS
BSc (London), MB Bchir (Cambridge), FRCP Edin, FAMS
Dr Toh is Senior Consultant and former Head at the Department of Medical Oncology and now Deputy Director, National Cancer Centre, Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is also alumni at the Harvard Business School. He is currently the vice-chairman of the Oncology Academic Clinical Program (ACP) for Education.
He is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. Dr Toh is an Associate Professor and College Master at the Duke-NUS Graduate Medical School. He is also an adjunct Principal Investigator at the Institute of Molecular and Cell Biology, A*STAR. He was a council member in the Singapore Medical Association and the Singapore College of Physicians.
Dr Toh has published 93 per review journal papers to date including in Nature Reviews Clinical Oncology, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research and Stem Cells.
|• 2014 The Academia @ Singhealth SG- GCP Course|
• 2013 Harvard Business School 15th General Management Program
• 2003 Fellowship of the Royal College of Physicians, Edinburgh. – FRCP
• 1994 Membership of the Royal College of Physicians, UK. - MRCP
• 1990 University of Cambridge School of Clinical Medicine, UK. - MBBChir
• 1987 Wright-Fleming Institute, St Mary’s Hospital Medical School, University of London, UK - Intercalated BSc in Infection & Immunity (Upper Second Class Honours)
• 1986 Royal Free Hospital School of Medicine, University of London, UK Preclinical Course
• 2014- Current Adjunct PI, Institute of Molecular and Cell Biology, A*STAR, Biopolis Singapore
• 2013- Current Vice Chairman, Oncology ACP for Education
• 2013- Current Deputy Director, National Cancer Centre Singapore
• 2011- Current Associate Professor, Cancer & Stem Cell Biology Program, Duke-NUS GMS, Singapore
• 2011- Current Chairman, Cell Tissue-Based Therapy Committee, National Cancer Centre Singapore
• 2011- Current Chairman, Cell Tissue-Based Therapy Committee, National Cancer Centre Singapore
• 2010- Current College Master for Eugene Stead College, Duke-NUS GMS
• 2009- 2013 Head, Division of Medical Oncology, National Cancer Centre Singapore
• 2004- Current Senior Consultant, Division of Medical Oncology, National Cancer Centre, Singapore.
• 2001- 2004 Consultant, Division of Medical Oncology, National Cancer Centre, Singapore.
• 2004- 2007 Chairman, Chapter of Oncology, Singapore College of Physicians
• 2004-2011 Editor, Singapore Medical Association Council
• 2004-2006 President, Singapore Society of Oncology
• 2003- 2004 Vice-president, Singapore Society of Oncology
• 2003 Fellow, Royal College of Medicine, Edinburgh
• 2000-2001 Associate Consultant, Division of Medical Oncology, National Cancer Centre, Singapore.
• 1999- Current Principal Investigator, Laboratory of Cell Therapy and Cancer Vaccine, Division of Medical Oncology, National Cancer Centre Singapore
• 1999- Current Director, Cryopreservation Laboratory, Division of Medical Oncology, National Cancer Centre Singapore
• 1999- 2000 Research Fellow, Centre for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, United States.
• 1997-1999 Clinical and Clinical Research Fellow, Division of Haematology-Oncology and Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Centre, Harvard Medical School, Boston, MA 02114, USA.
• 1998-2000 Senior Registrar, Department of Medical Oncology, National Cancer Centre, Singapore.
• 1995-1997 Fellow / Registrar, Department of Medical Oncology, Singapore General Hospital, Singapore.
• 1992-1995 Resident in Internal Medicine, Rehabilitation Medicine, Cardiology and Accident & Emergency, Tan Tock Seng Hospital and Alexandra Hospital, Singapore.
• 1991-1992 Singapore Armed Forces Medical Corp. National Service Military Medical Officer (Captain). Reservist Infantry Medical Officer in 67 Guards Battalion, Singapore. (1992 - present)
• 1990-1991 House Officer, Departments of Medicine, Surgery and Paediatrics, National University Hospital, Singapore.
• Member, American Society of Clinical Oncology
• Member, European Society of Medical Oncology
• Fellow, Academy of Medicine, Singapore
• Member, Medical Oncology Residency Advisory Committee
1. College Master and Associate Professor, Cancer & Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore
2. Vice-Chair Oncology ACP (Education), SingHealth-Duke-NUS
3. Clinical Senior Lecturer, YLLSOM, NUS
4. Adjuct PI, Institute of Molecular and Cell Biology, A*STAR
5. National Cancer Task Force Committee
6. National Residency Advisory Committee for Medical Oncology
• 2016 Duke-SingHealth AM-ETHOS Mentoring Award to Duke University Health System
• 2016 Outstanding Poster Presentation Award, Gordon Research Conference for Nasopharyngeal Carcinoma, Hong Kong
• 2009 National Medical Research Council Clinician Scientist Award
• 2008 Duke-NUS Graduate Medical School Best Teacher Award (Molecules and Cells)
• 2004 National Excellent Service Award (Star Award)
• 1999- 2000 Singapore Cancer Society Overseas Fellowship Award.
• 1998-1999 Singapore General Hospital Fellowship Award.
• 1997-1998 Singapore Health Manpower Development Plan Fellowship Award.
• 1996 First Prize, 7th Singapore General Hospital Annual Scientific Meeting Commemorative Essay Competition.
• 1981-1983 United World College Scholarship, to the Lester B. Pearson College of the Pacific, British Columbia, Canada to read for the International Baccalaureate.
• Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V. Gut. 2017 Feb;66(2):342-35
• Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay JC, Toh HC, Connolly JE, Xu XH, Wang S. Oncotarget. 2017 Jan 10.
• A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP. Ann Oncol. 2016 Dec;27(12):2210-2215.
• National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.
• Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. Liver Cancer. 2016 Apr;5(2):97-106.
• Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection. Yaligar J, Teoh WW, Othman R, Verma SK, Phang BH, Lee SS, Wang WW, Toh HC, Gopalan V, Sabapathy K, Velan SS. Sci Rep. 2016 Feb 2;6:20299.
• Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2015 Jan 10;33(2):172-9.
• Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG (2014) Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet 46(1) : 24-32
• Chua C, Tan IB, Choo SP, Toh HC (2013) Increased a-Fetoprotein Likely Induced by Complementary Health Products. J Clin Oncol 31(6) : e80-2
• Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP (2012) Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients. J Natl Cancer Inst 104(23) : 1796-807
• Chia WK, Ali R, Toh HC (2012) Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 9(10) : 561-70
• Chew V, Chen J, Lee D, Loh E, Lee J(HK), Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP (2012) Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61(3) : 427-438
• Chay WY, Teo M, Sittampalam K, Toh HC (2011) Effective Use of Thalidomide in the Treatment of Recurrent Metastatic Chordoma . J Clin Oncol 29(16) : e477-e480
• Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P (2011) Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 141(2) : 476-485.e11
• Toh HC, Teo M, Ong KW, Lee V, Chan E, Lee AS, Vathsala A (2006) Use of sirolimus for Epstein-Barr virus-positive smooth-muscle tumour. Lancet Oncol 7(11) : 955-957
Research trials :
• Study Chair: A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients
• Study Chair: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial
• Principal Investigator: Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers
• PI (site) S*Bio: A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced malignancies
• Co-PI: A Phase I Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
• PI: Phase II Trial Evaluating Efficacy of a Strategy Employing Combination Gemcitabine and Carboplatin Chemotherapy Followed by EBV-Specific Cytotoxic T-Lymphocytes in Patients With Metastatic or Locally Recurrent EBV-Positive Nasopharyngeal Carcinoma
• Study Chair: Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma
• PI: Phase II Allogeneic non-myeloablative conditioning and delayed donor leukocyte infusions (DLI) for HLA matched and 1-antigen mismatched peripheral blood stem cell transplantation (PBSCT) for chemorefractory nasopharyngeal carcinoma (First-in-Man)
• PI: Prospective phase II clinical trial of vaccination with autologous dendritic cells loaded with lysate of allogenic melanoma cells (MelCancerVac) for treatment of patients with advanced colorectal cancer
• PI (site) Abbott: An open-label, phase 2 study of efficacy and tolerability of ABT-869 in advanced hepatocellular carcinoma
• PI (site) Roche: Modified-dose capecitabine (Xeloda) plus Bevacizumab (Avastin) for the treatment of advanced or metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study
• PI (site) CTRG: A phase I/II study of PXD101 in patients with unresectable hepatocellular carcinoma with pharmacokinetic and pharmacodynamic evaluation